The potential of statins for individualized colorectal cancer chemoprevention

Current Drug Targets

Volumn 12, Issue 13, 2011, Pages 1903-1908

  Jacobs, Rutger J ^a   Kodach, Liudmila L ^a   Hardwick, James C H ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Bone morphogenetic protein; Chemoprevention; Colorectal cancer; Statins

Indexed keywords

ANTIGEN; BONE MORPHOGENETIC PROTEIN; BONE MORPHOGENETIC PROTEIN RECEPTOR 1A; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISOPRENOID; LEUKOCYTE FUNCTION ANTIGEN 1; MEVALONIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT; RAS PROTEIN; RHO FACTOR; ROFECOXIB; SMAD PROTEIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER ADJUVANT THERAPY; CANCER INCIDENCE; CANCER INHIBITION; CANCER PREVENTION; CANCER RISK; CANCER SCREENING; CANCER SURVIVAL; CHEMOPROPHYLAXIS; CHOLESTEROL BLOOD LEVEL; COLON POLYP; COLORECTAL CANCER; DRUG MECHANISM; DRUG TOLERABILITY; EARLY DIAGNOSIS; ENTERITIS; ENVIRONMENTAL FACTOR; HEREDITY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INDIVIDUALIZATION; METASTASIS; MOLECULAR MECHANICS; NONHUMAN; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK BENEFIT ANALYSIS; TUMOR GROWTH;

ANIMALS; BONE MORPHOGENETIC PROTEINS; CHEMOPREVENTION; COLORECTAL NEOPLASMS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INDIVIDUALIZED MEDICINE; MICE; RATS; RISK ASSESSMENT;

EID: 82055197154     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/138945011798184182     Document Type: Article

References (68)

1. Coleman MP, Quaresma M, Berrino F, et al. Cancer survival in five continents: a worldwide population-based study (CONCORD). Lancet Oncol 2008; 9: 730-56.
2. Berrino F, De Angelis R, Sant M, et al. Survival for eight major cancers and all cancers combined for European adults diagnosed in 1995-99: results of the EUROCARE-4 study. Lancet Oncol 2007; 8: 773-83.
3. Coleman MP, Gatta G, Verdecchia A, et al. EUROCARE-3 summary: cancer survival in Europe at the end of the 20th century. Ann Oncol 2003; 14: v128-v149.
4. Karim-Kos HE, de Vries E, Soerjomataram I, et al. Recent trends of cancer in Europe: A combined approach of incidence, survival and mortality for 17 cancer sites since the 1990s. Eur J Cancer 2008; 44: 1345-89.
5. Scholefield JH, Moss S, Sufi F, et al. Effect of faecal occult blood screening on mortality from colorectal cancer: results from a randomised controlled trial. Gut 2002; 50: 840-4.
6. de Jong AE, Hendriks YM, Kleibeuker JH, et al. Decrease in mortality in Lynch syndrome families because of surveillance. Gastroenterology 2006; 130: 665-71.
7. Pollard M, Luckert PH. Effect of indomethacin on intestinal tumors induced in rats by the acetate derivative of dimethylnitrosamine. Science 1981; 214: 558-9.
8. Waddell WR, Loughry RW. Sulindac for polyposis of the colon. J Surg Oncol 1983; 24: 83-7.
9. Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008; 359: 1757-65.
10. Newman TB, Hulley SB. Carcinogenicity of lipid-lowering drugs. JAMA 1996; 275: 55-60.
11. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebocontrolled trial. Lancet 2002; 360: 7-22.
12. Blais L, Desgagne A, LeLorier J. 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors and the Risk of Cancer: A Nested Case-Control Study. Arch Intern Med 2000; 160: 2363-8.
13. Downs JR, Clearfield M, Tyroler HA, et al. Air force/texas coronary atherosclerosis prevention study (afcaps/texcaps): Additional perspectives on tolerability of long-term treatment with lovastatin. Am J Cardiol 2001; 87: 1074-9.
14. Graaf MR, Beiderbeck AB, Egberts ACG, et al. The Risk of Cancer in Users of Statins. J Clin Oncol 2004; 22: 2388-94.
15. Sacks FM, Pfeffer MA, Moye LA, et al. The Effect of Pravastatin on Coronary Events after Myocardial Infarction in Patients with Average Cholesterol Levels. N Engl J Med 1996; 335: 1001-9.
16. Serruys PWJC, de Feyter P, Macaya C, et al. Fluvastatin for Prevention of Cardiac Events Following Successful First Percutaneous Coronary Intervention: A Randomized Controlled Trial. JAMA 2002; 287: 3215-22.
17. Shepherd J, Cobbe SM, Ford I, et al. Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia. N Engl J Med 1995; 333: 1301-8.
18. Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002; 360: 1623-30.
19. Strandberg TE, Pyorala K, Cook TJ, et al. Mortality and incidence of cancer during 10-year follow-up of the Scandinavian Simvastatin Survival Study (4S). Lancet 2004; 364: 771-7.
20. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major Outcomes in Moderately Hypercholesterolemic, Hypertensive Patients Randomized to Pravastatin vs. Usual Care: The Antihypertensive and Lipid- Lowering Treatment to Prevent Heart Attack Trial (ALLHATLLT). JAMA 2002; 288: 2998-3007.
21. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol Levels. N Engl J Med 1998; 339: 1349-57.
22. Friis S, Poulsen AH, Johnsen SP, et al. Cancer risk among statin users: a population-based cohort study. Int J Cancer 2005; 114: 643-7.
23. Poynter JN, Gruber SB, Higgins PD, et al. Statins and the risk of colorectal cancer. N Engl J Med 2005; 352: 2184-92.
24. Katz MS. Therapy insight: Potential of statins for cancer chemoprevention and therapy. Nat Clin Pract Oncol 2005; 2: 82-9.
25. Singh H, Mahmud SM, Turner D, et al. Long-term use of statins and risk of colorectal cancer: a population-based study. Am J Gastroenterol 2009; 104: 3015-23.
26. Jacobs EJ, Rodriguez C, Brady KA, et al. Cholesterol-Lowering Drugs and Colorectal Cancer Incidence in a Large United States Cohort. JNCI Cancer Spectrum 2006; 98: 69-72.
27. Hachem C, Morgan R, Johnson M, et al. Statins and the risk of colorectal carcinoma: a nested case-control study in veterans with diabetes. Am J Gastroenterol 2009; 104: 1241-8.
28. Siddiqui AA, Nazario H, Mahgoub A, et al. For patients with colorectal cancer, the long-term use of statins is associated with better clinical outcomes. Digest Dis Sci 2009; 54: 1307-11.
29. Siddiqui AA, Nazario H, Mahgoub A, et al. The long-term use of statins is associated with a decreased incidence of adenomatous colon polyps. Digestion 2009; 79: 17-22.
30. Bardou M, Barkun A, Martel M. Effect of statin therapy on colorectal cancer. Gut 2010.
31. Bonovas S, Filioussi K, Flordellis CS, Sitaras NM. Statins and the Risk of Colorectal Cancer: A Meta-Analysis of 18 Studies Involving More Than 1.5 Million Patients. J Clin Oncol 2007; 25: 3462-8.
32. Dale KM, Coleman CI, Henyan NN, et al. Statins and Cancer Risk: A Meta-analysis. JAMA 2006; 295: 74-80.
33. Narisawa T, Morotomi M, Fukaura Y, et al. Chemoprevention by pravastatin, a 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor, of N-methyl-N-nitrosourea-induced colon carcinogenesis in F344 rats. Jpn J Cancer Res 1996; 87: 798-804.
34. Narisawa T, Fukaura Y, Terada K, et al. Prevention of 1,2- dimethylhydrazine-induced colon tumorigenesis by HMG-CoA reductase inhibitors, pravastatin and simvastatin, in ICR mice. Carcinogenesis 1994; 15: 2045-8.
35. Agarwal B, Rao CV, Bhendwal S, et al. Lovastatin augments sulindac-induced apoptosis in colon cancer cells and potentiates chemopreventive effects of sulindac. Gastroenterology 1999; 117: 838-47.
36. Swamy MV, Patlolla JM, Steele VE, et al. Chemoprevention of familial adenomatous polyposis by low doses of atorvastatin and celecoxib given individually and in combination to APCMin mice. Cancer Res 2006; 66: 7370-7.
37. Kim KP, Whitehead C, Piazza G, Wargovich MJ. Combinatorial chemoprevention: efficacy of lovostatin and exisulind on the formation and progression of aberrant crypt foci. Anticancer Res 2004; 24: 1805-11.
38. Taras D, Blanc JF, Rullier A, et al. Pravastatin reduces lung metastasis of rat hepatocellular carcinoma via a coordinated decrease of MMP expression and activity. J Hepatol 2007; 46: 69-76.
39. Holstein SA, Knapp HR, Clamon GH, et al. Pharmacodynamic effects of high dose lovastatin in subjects with advanced malignancies. Cancer Chemother Pharmacol 2006; 57: 155-64.
40. Narisawa T, Fukaura Y, Tanida N, et al. Chemopreventive efficacy of low dose of pravastatin, an HMG-CoA reductase inhibitor, on 1,2-dimethylhydrazine-induced colon carcinogenesis in ICR mice. Tohoku J Exp Med 1996; 180: 131-8.
41. Wong WWL. HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis. Leukemia 2002; 16: 508-19.
42. Zhang C, Schmidt M, von Eichei-Streiber C, Jakobs KH. Inhibition by toxin B of inositol phosphate formation induced by G proteincoupled and tyrosine kinase receptors in N1E-115 neuroblastoma cells: involvement of Rho proteins. Mol Pharmacol 1996; 50: 864-9.
43. Demierre MF, Higgins PDR, Gruber SB, et al. Statins and cancer prevention. Nat Rev Cancer 2005; 5: 930-42.
44. Mo H, Elson CE. Studies of the Isoprenoid-Mediated Inhibition of Mevalonate Synthesis Applied to Cancer Chemotherapy and Chemoprevention. Exp Biol Med 2004; 229: 567-85.
45. Muller C, Bockhorn AG, Klusmeier S, et al. Lovastatin inhibits proliferation of pancreatic cancer cell lines with mutant as well as with wild-type K-ras oncogene but has different effects on protein phosphorylation and induction of apoptosis. Int J Oncol 1998; 12: 717-23.
46. Agarwal B, Halmos B, Feoktistov AS, et al. Mechanism of lovastatin-induced apoptosis in intestinal epithelial cells. Carcinogenesis 2002; 23: 521-8.
47. Ng K, Ogino S, Meyerhardt JA, et al. Relationship Between Statin Use and Colon Cancer Recurrence and Survival: Results From CALGB 89803. J Natl Cancer Inst 2011.
48. Weitz-Schmidt G, Welzenbach K, Brinkmann V, et al. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat Med 2001; 7: 687-92.
49. Kodach LL, Bleuming SA, Peppelenbosch MP, et al. The effect of statins in colorectal cancer is mediated through the bone morphogenetic protein pathway. Gastroenterology 2007; 133: 1272-81.
50. Mundy G, Garrett R, Harris S, et al. Stimulation of Bone Formation in Vitro and in Rodents by Statins. Science 1999; 286: 1946-9.
51. Riggins GJ, Kinzler KW, Vogelstein B, Thiagalingam S. Frequency of Smad gene mutations in human cancers. Cancer Res 1997; 57: 2578-80.
52. Alazzouzi H, Alhopuro P, Salovaara R, et al. SMAD4 as a prognostic marker in colorectal cancer. Clin Cancer Res 2005; 11: 2606-11.
53. Hardwick JC, van den Brink GR, Bleuming SA, et al. Bone morphogenetic protein 2 is expressed by, and acts upon, mature epithelial cells in the colon. Gastroenterology 2004; 126: 111-21.
54. Auclair BA, Benoit YD, Rivard N, et al. Bone morphogenetic protein signaling is essential for terminal differentiation of theintestinal secretory cell lineage 1. Gastroenterology 2007; 133: 887-96.
55. Howe JR, Roth S, Ringold JC, et al. Mutations in the SMAD4/ DPC4 gene in juvenile polyposis. Science 1998; 280: 1086-8.
56. Howe JR, Bair JL, Sayed MG, et al. Germline mutations of the gene encoding bone morphogenetic protein receptor 1A in juvenile polyposis. Nat Genet 2001; 28: 184-7.
57. Broderick P, Carvajal-Carmona L, Pittman AM, et al. A genomewide association study shows that common alleles of SMAD7 influence colorectal cancer risk. Nat Genet 2007; 39: 1315-7.
58. Houlston RS, Webb E, Broderick P, et al. Meta-analysis of genome-wide association data identifies four new susceptibility loci for colorectal cancer. Nat Genet 2008; 40: 1426-35.
59. Jaeger E, Webb E, Howarth K, et al. Common genetic variants at the CRAC1 (HMPS) locus on chromosome 15q13.3 influence colorectal cancer risk. Nat Genet 2008; 40: 26-8.
60. Samowitz WS, Albertsen H, Sweeney C, et al. Association of Smoking, CpG Island Methylator Phenotype, and V600E BRAF Mutations in Colon Cancer. J Natl Cancer Inst 2006; 98: 1731-8.
61. Bresalier RS, Sandler RS, Quan H, et al. Cardiovascular Events Associated with Rofecoxib in a Colorectal Adenoma Chemoprevention Trial. New Engl J Med 2005; 352: 1092-102.
62. Bernini F, Poli A, Paoletti R. Safety of HMG-CoA reductase inhibitors: focus on atorvastatin. Cardiovasc Drugs Ther 2001; 15: 211-8.
63. Hippisley-Cox J, Coupland C. Unintended effects of statins in men and women in England and Wales: population based cohort study using the QResearch database. BMJ 340.
64. Golomb BA, Evans MA. Statin adverse effects: a review of the literature and evidence for a mitochondrial mechanism. Am J Cardiovasc Drugs 2008; 8: 373-418.
65. Thibault A, Samid D, Tompkins AC, et al. Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer. Clin Cancer Res 1996; 2: 483-91.
66. Xiao H, Yang CS. Combination regimen with statins and NSAIDs: a promising strategy for cancer chemoprevention. Int J Cancer 2008; 123: 983-90.
67. Gutierrez G, Lalka D, Garrett I, et al. Transdermal application of lovastatin to rats causes profound increases in bone formation and plasma concentrations. Osteoporosis Internatl 2006; 17: 1033-42.
68. Burn J, Bishop DT, Mecklin JP, et al. Effect of Aspirin or Resistant Starch on Colorectal Neoplasia in the Lynch Syndrome. New Engl J Med 2009; 359: 2567-78.